Return on capital (ROC) is after tax rate of return on net business assets. ROIC is unaffected by changes in interest rates or company debt and equity structure. It measures business productivity performance.
Return on Invested Capital (ROIC)
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net operating profit after taxes (NOPAT)1 | 1,268) | 1,678) | 718) | 449) | 444) | |
| Invested capital2 | 21,926) | 21,241) | 21,108) | 20,313) | 20,458) | |
| Performance Ratio | ||||||
| ROIC3 | 5.78% | 7.90% | 3.40% | 2.21% | 2.17% | |
| Benchmarks | ||||||
| ROIC, Competitors4 | ||||||
| AbbVie Inc. | 14.05% | 12.89% | — | — | — | |
| Amgen Inc. | 16.11% | 15.93% | — | — | — | |
| Bristol-Myers Squibb Co. | 6.37% | 8.29% | — | — | — | |
| Danaher Corp. | 8.76% | 9.01% | — | — | — | |
| Eli Lilly & Co. | 17.98% | 19.39% | — | — | — | |
| Gilead Sciences Inc. | 8.09% | 14.43% | — | — | — | |
| Johnson & Johnson | 14.16% | 19.23% | — | — | — | |
| Merck & Co. Inc. | 19.14% | 18.87% | — | — | — | |
| Pfizer Inc. | 28.01% | 20.98% | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 28.87% | 72.50% | — | — | — | |
| Thermo Fisher Scientific Inc. | 7.76% | 9.42% | — | — | — | |
| Vertex Pharmaceuticals Inc. | 22.66% | 23.86% | — | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 NOPAT. See details »
2 Invested capital. See details »
3 2022 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × 1,268 ÷ 21,926 = 5.78%
4 Click competitor name to see calculations.
The Return on Invested Capital (ROIC) exhibits a general upward trajectory from 2018 through 2021, followed by a moderate decline in 2022. The metric rose from a baseline of 2.17% in 2018 to a peak of 7.90% in 2021, before settling at 5.78% at the end of 2022.
- Net Operating Profit After Taxes (NOPAT)
- A significant expansion in NOPAT is observed over the period, specifically between 2020 and 2021, where values surged from US$ 718 million to US$ 1,678 million. Although NOPAT decreased to US$ 1,268 million in 2022, the figure remains substantially higher than the levels maintained between 2018 and 2020.
- Invested Capital
- Invested capital remained relatively stable with a slight upward trend, moving from US$ 20,458 million in 2018 to US$ 21,926 million in 2022. The lack of significant volatility in the capital base indicates that the fluctuations in ROIC were driven by changes in operating profitability rather than aggressive changes in capital deployment or divestment.
- ROIC Efficiency and Correlation
- The peak in ROIC during 2021 is directly attributable to the sharp increase in NOPAT relative to a nearly stagnant capital base. The subsequent decline in 2022 to 5.78% reflects a dual impact: a reduction in NOPAT coupled with a continued increase in invested capital, resulting in lower overall capital efficiency compared to the previous year.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Decomposition of ROIC
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 Operating profit margin (OPM). See calculations »
2 Turnover of capital (TO). See calculations »
3 Effective cash tax rate (CTR). See calculations »
The Return on Invested Capital (ROIC) exhibited a consistent upward trajectory from 2018 to 2021, rising from 2.17% to a peak of 7.90%, before contracting to 5.78% in 2022. This overall trend was driven by the combined expansion of operating profitability, improved capital efficiency, and a favorable shift in the effective tax burden.
- Operating Profit Margin (OPM)
- Profitability showed significant expansion over the analyzed period. After remaining relatively stagnant between 2018 (7.51%) and 2019 (7.26%), the margin climbed sharply to a peak of 14.31% in 2021. The subsequent decline to 12.08% in 2022 acted as a primary contributor to the reduction in the final ROIC figure.
- Turnover of Capital (TO)
- Capital efficiency improved steadily, with the turnover ratio increasing from 0.51 in 2018 to 0.68 in 2021. This indicates an enhanced ability to generate revenue from the invested capital base. A slight correction to 0.66 was observed in 2022, mirroring the broader trend of decline from the 2021 peak.
- Effective Cash Tax Rate Impact (1 – CTR)
- The proportion of operating profit retained after taxes increased substantially, moving from 56.62% in 2018 to a peak of 81.15% in 2021. This reduction in the effective tax burden served as a powerful multiplier, accelerating ROIC growth through 2021 before moderating to 72.99% in 2022.
The peak ROIC observed in 2021 was the result of a synchronized optimization across all three decomposition components: maximum operating margins, peak capital turnover, and the most favorable tax impact. The decline in 2022 reflects a simultaneous retreat across each of these three metrics.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Operating Profit Margin (OPM)
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net operating profit after taxes (NOPAT)1 | 1,268) | 1,678) | 718) | 449) | 444) | |
| Add: Cash operating taxes2 | 469) | 390) | 334) | 356) | 340) | |
| Net operating profit before taxes (NOPBT) | 1,737) | 2,067) | 1,052) | 805) | 784) | |
| Revenues | 14,410) | 13,874) | 11,359) | 11,088) | 10,412) | |
| Add: Increase (decrease) in unearned income | (28) | 573) | 238) | 7) | 22) | |
| Adjusted revenues | 14,382) | 14,447) | 11,597) | 11,095) | 10,434) | |
| Profitability Ratio | ||||||
| OPM3 | 12.08% | 14.31% | 9.07% | 7.26% | 7.51% | |
| Benchmarks | ||||||
| OPM, Competitors4 | ||||||
| AbbVie Inc. | 26.77% | 27.06% | — | — | — | |
| Amgen Inc. | 35.35% | 32.55% | — | — | — | |
| Bristol-Myers Squibb Co. | 19.38% | 20.31% | — | — | — | |
| Danaher Corp. | 27.12% | 27.65% | — | — | — | |
| Eli Lilly & Co. | 25.19% | 23.01% | — | — | — | |
| Gilead Sciences Inc. | 24.71% | 34.43% | — | — | — | |
| Johnson & Johnson | 22.67% | 24.39% | — | — | — | |
| Merck & Co. Inc. | 30.22% | 30.60% | — | — | — | |
| Pfizer Inc. | 38.53% | 29.86% | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 39.28% | 57.80% | — | — | — | |
| Thermo Fisher Scientific Inc. | 18.33% | 23.92% | — | — | — | |
| Vertex Pharmaceuticals Inc. | 46.55% | 36.91% | — | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2022 Calculation
OPM = 100 × NOPBT ÷ Adjusted revenues
= 100 × 1,737 ÷ 14,382 = 12.08%
4 Click competitor name to see calculations.
The financial performance between 2018 and 2022 is characterized by a significant expansion in operating profitability, peaking in 2021 followed by a moderate correction in 2022. While revenue grew steadily over the period, the growth in net operating profit before taxes (NOPBT) outpaced revenue growth, leading to a substantial improvement in the operating profit margin (OPM).
- Revenue and Profitability Growth
- Adjusted revenues increased from 10,434 million US$ in 2018 to 14,382 million US$ in 2022. During this same interval, NOPBT rose from 784 million US$ to 1,737 million US$, representing a growth rate significantly higher than that of the top line. This divergence indicates an improvement in operational efficiency and cost management.
- Operating Profit Margin Trends
- The operating profit margin remained relatively stable between 2018 and 2019, moving from 7.51% to 7.26%. A positive trend emerged in 2020 with an increase to 9.07%, which accelerated sharply in 2021 to a peak of 14.31%. This represents a nearly twofold increase in margin efficiency within a three-year window.
- Recent Performance Correction
- In 2022, a contraction in the operating profit margin was observed, falling to 12.08% from the 14.31% high of the previous year. This decline occurred despite revenues remaining nearly flat, decreasing only slightly from 14,447 million US$ to 14,382 million US$. The corresponding drop in NOPBT to 1,737 million US$ suggests an increase in operating expenses or a shift in the cost of goods sold during the final year of the analyzed period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Turnover of Capital (TO)
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Revenues | 14,410) | 13,874) | 11,359) | 11,088) | 10,412) | |
| Add: Increase (decrease) in unearned income | (28) | 573) | 238) | 7) | 22) | |
| Adjusted revenues | 14,382) | 14,447) | 11,597) | 11,095) | 10,434) | |
| Invested capital1 | 21,926) | 21,241) | 21,108) | 20,313) | 20,458) | |
| Efficiency Ratio | ||||||
| TO2 | 0.66 | 0.68 | 0.55 | 0.55 | 0.51 | |
| Benchmarks | ||||||
| TO, Competitors3 | ||||||
| AbbVie Inc. | 0.71 | 0.59 | — | — | — | |
| Amgen Inc. | 0.62 | 0.60 | — | — | — | |
| Bristol-Myers Squibb Co. | 0.64 | 0.58 | — | — | — | |
| Danaher Corp. | 0.40 | 0.40 | — | — | — | |
| Eli Lilly & Co. | 1.18 | 1.08 | — | — | — | |
| Gilead Sciences Inc. | 0.59 | 0.57 | — | — | — | |
| Johnson & Johnson | 0.83 | 0.96 | — | — | — | |
| Merck & Co. Inc. | 0.80 | 0.69 | — | — | — | |
| Pfizer Inc. | 0.91 | 0.94 | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 0.99 | 1.48 | — | — | — | |
| Thermo Fisher Scientific Inc. | 0.54 | 0.49 | — | — | — | |
| Vertex Pharmaceuticals Inc. | 0.68 | 0.81 | — | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 Invested capital. See details »
2 2022 Calculation
TO = Adjusted revenues ÷ Invested capital
= 14,382 ÷ 21,926 = 0.66
3 Click competitor name to see calculations.
The financial performance from 2018 to 2022 demonstrates a progressive improvement in capital utilization efficiency, characterized by revenue growth that significantly outpaced the expansion of the invested capital base.
- Adjusted Revenue Growth
- Adjusted revenues exhibited a strong upward trajectory for most of the analyzed period, increasing from 10,434 million US$ in 2018 to a peak of 14,447 million US$ in 2021. While a slight decrease to 14,382 million US$ was observed in 2022, the overall trend reflects a substantial expansion in the company's top-line performance.
- Invested Capital Trends
- The invested capital remained relatively stable over the five-year window. After a slight decline in 2019 to 20,313 million US$, the capital base grew gradually to reach 21,926 million US$ by December 31, 2022. The limited growth in invested capital relative to the increase in revenues indicates a disciplined approach to capital deployment.
- Capital Turnover Efficiency
- The turnover of capital ratio improved from 0.51 in 2018 to 0.66 in 2022. The most significant leap occurred between 2020 and 2021, where the ratio rose from 0.55 to 0.68, directly correlating with the surge in adjusted revenues. This trend signifies an enhanced ability to generate revenue from the existing capital investment, reflecting increased operational productivity.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Effective Cash Tax Rate (CTR)
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net operating profit after taxes (NOPAT)1 | 1,268) | 1,678) | 718) | 449) | 444) | |
| Add: Cash operating taxes2 | 469) | 390) | 334) | 356) | 340) | |
| Net operating profit before taxes (NOPBT) | 1,737) | 2,067) | 1,052) | 805) | 784) | |
| Tax Rate | ||||||
| CTR3 | 27.01% | 18.85% | 31.78% | 44.20% | 43.38% | |
| Benchmarks | ||||||
| CTR, Competitors4 | ||||||
| AbbVie Inc. | 25.72% | 18.70% | — | — | — | |
| Amgen Inc. | 27.01% | 18.93% | — | — | — | |
| Bristol-Myers Squibb Co. | 48.91% | 29.34% | — | — | — | |
| Danaher Corp. | 19.69% | 18.58% | — | — | — | |
| Eli Lilly & Co. | 39.25% | 22.28% | — | — | — | |
| Gilead Sciences Inc. | 44.70% | 25.84% | — | — | — | |
| Johnson & Johnson | 25.14% | 17.53% | — | — | — | |
| Merck & Co. Inc. | 20.99% | 10.42% | — | — | — | |
| Pfizer Inc. | 20.44% | 25.02% | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 26.00% | 15.19% | — | — | — | |
| Thermo Fisher Scientific Inc. | 21.94% | 19.89% | — | — | — | |
| Vertex Pharmaceuticals Inc. | 28.16% | 19.91% | — | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2022 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × 469 ÷ 1,737 = 27.01%
4 Click competitor name to see calculations.
The financial trajectory from 2018 to 2022 reveals a significant divergence between the growth of net operating profit before taxes (NOPBT) and the effective cash tax rate (CTR). While operating profitability expanded substantially, the cash tax burden as a percentage of that profit experienced a sharp decline before a partial recovery in the final year of the period.
- Effective Cash Tax Rate Volatility
- The CTR began at a high plateau, remaining stable between 43.38% in 2018 and 44.20% in 2019. A decisive downward trend followed, with the rate dropping to 31.78% in 2020 and reaching a period low of 18.85% in 2021. This represents a contraction of approximately 25 percentage points from the 2019 peak. However, this trend reversed in 2022, as the CTR climbed back to 27.01%.
- Net Operating Profit Before Taxes (NOPBT) Growth
- Operating profitability demonstrated strong upward momentum, increasing from 784 million US dollars in 2018 to a peak of 2,067 million US dollars in 2021. Despite a moderation to 1,737 million US dollars in 2022, the profit levels remained significantly higher than those observed in the 2018-2019 period.
- Cash Operating Tax Trends
- Cash operating taxes exhibited a general increase over the five-year span, rising from 340 million US dollars in 2018 to 469 million US dollars in 2022. The growth in absolute tax payments was less aggressive than the growth in NOPBT, particularly between 2020 and 2021, which explains the simultaneous decline in the effective tax rate.
- Correlation Analysis
- The most notable anomaly occurred in 2021, where NOPBT reached its maximum value of 2,067 million US dollars while the CTR hit its minimum of 18.85%. This indicates a period of peak tax efficiency or the utilization of significant tax shields. The subsequent increase in the CTR in 2022, coupled with a decline in NOPBT, suggests a normalization of the tax burden relative to operating earnings.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?